Clinical Evidence
Why Clinical Studies Matter Under MDR
- Clinical safety
- Clinical performance
- Clinical benefit
This is achieved through a Clinical Evaluation (Article 61, Annex XIV), often supported by clinical investigations (Annex XV). For many Class IIa, IIb, and III devices, clinical studies are no longer optional they are a regulatory and commercial necessity. Strong clinical evidence doesn’t just satisfy regulators, it builds trust with clinicians, payers, and patients.
Strong clinical evidence doesn’t just satisfy regulators—it builds trust with clinicians, payers, and patients.
Prospective Clinical Studies
A prospective clinical study is a planned investigation where patients are followed forward in time after receiving the device. Outcomes are predefined and collected according to a Clinical Investigation Plan (CIP). These studies may be:
- Single-arm (device only)
- Comparative (against standard of care or literature benchmarks)
When Prospective Studies Work Best
Prospective studies are widely accepted under MDR when:
- The device is Class IIa or IIb
- The technology is incremental or well-established
- Clinical benefit is already known
- Randomization is impractical or unethical
Key Benefits
- Faster study start-up
- Lower cost and complexity
- Strong real-world relevance
- Often sufficient for CE marking when well justified
Limitations
- Higher potential for bias
- Weaker evidence for novel or high-risk devices
- May not support superiority claims
Randomized Controlled Trials (RCTs)
When MDR Typically Expects an RCT
Notified Bodies often expect RCTs for:
- Class III devices
- Implantable devices
- Novel or breakthrough technologies
- Claims of superior clinical performance
Key Benefits
- Highest level of scientific credibility
- Minimizes bias
- Strong support for benefit–risk assessment
- Highly persuasive for regulators and investors
Limitations
- Higher cost and longer timelines
- Operational and ethical challenges
- Not always feasible for every device
Prospective Study vs RCT — At a Glance
| Feature | Prospective Study | Randomised Controlled Trial |
|---|---|---|
| Study design | Observational or comparative | Comparative |
| Randomisation | No | Yes |
| Evidence strength | Moderate | High |
| Typical MDR use | Class IIa / IIb | Class IIb / III |
| Cost & complexity | Lower | Higher |
| Suitable for novel devices | Sometimes | Preferred |
Choosing the Right Clinical Strategy
A Prospective Study May Be Sufficient If:
- Your device is an iteration of existing technology
- You can justify a state-of-the-art comparison
- The risk profile is moderate
- You aim for efficient market entry
An RCT Is Advisable If:
- Your device is innovative or implantable
- Clinical benefit is not yet established
- You claim superiority over existing solutions
- Long-term market acceptance is critical
Choosing the wrong study design is one of the most common causes of MDR delays.
Beyond CE Marking: The Market Value of Strong Clinical Evidence
Well-designed clinical studies can help you:
- Accelerate Notified Body approval
- Strengthen clinical adoption
- Support pricing and reimbursement
- Increase investor confidence
- Reduce post-market compliance risk
Clinical evidence is not just regulatory documentation—it is a commercial asset.
How We Help
We support medical device manufacturers with:
- Clinical strategy aligned to MDR expectations
- Study design (Prospective studies & RCTs)
- Clinical Investigation Plans (CIP)
- Clinical Evaluation Reports (CER)
- PMCF planning and execution
From clinical evidence to CE marking—and beyond.
Ready to Define Your Clinical Path?
The right clinical strategy can mean the difference between regulatory delay and market success. Let’s build evidence that regulators accept and markets trust.
Talk to us about your device class, novelty, and target claims to define a study approach that supports both CE marking and commercial adoption.
service related FAQ’s
The timeline varies based on device class and documentation readiness. Class I devices may take a few weeks, while Class IIa, IIb, and III devices requiring Notified Body review may take 6–12 months or more.
Any medical device or new in vitro diagnostic medical device that is imported or manufactured for the purpose of clinical investigation, clinical performance evaluation, testing, evaluation, demonstration, or training must be kept in containers with labels clearly indicating:
-
Name of the product or code number
-
Batch or lot number
-
Serial number (wherever applicable)
-
Date of manufacture
-
Use-before date
-
Storage conditions
-
Name and address of the manufacturer
-
The specific purpose for which it has been manufactured
-
“For Clinical Investigation / Evaluation Only – Not for Sale”
Not always. If sufficient historical data or literature exists to demonstrate the safety of materials used in the device, some tests may be waived. A gap analysis helps determine whether existing data is adequate or if additional testing (e.g., cytotoxicity, irritation, sensitization) is required to meet regulatory expectations.
Its highly recommended to conduct testing of finished salable device before you apply for regulatory clearance.
Some key documents include the Technical Documentation (Annex II & III), Clinical Evaluation Report (CER), Risk Management File, PMS/PMCF Plans, and labeling/instructions for use (IFU) compliant with GSPR
Form MD-22: This is the application form submitted to the Central Licensing Authority (CLA) (i.e., DCGI under CDSCO) to seek permission for conducting a clinical investigation of a new medical device or an investigational medical device without a predicate device in India.
Form MD-23: If the CLA is satisfied with the application, it grants permission to conduct the clinical investigation through Form MD-23. This permission allows the sponsor to begin the study in accordance with an approved clinical investigation plan reviewed by a registered Ethics Committee.
Additional requirements:
-
The clinical investigation must be registered with the Clinical Trials Registry – India (CTRI) before the enrolment of the first participant.
-
The first participant must be enrolled within one year of the grant of permission; otherwise, fresh permission from the CLA is required.
